Why is the CSL share price smashing the ASX 200 on Thursday?

A doctor appears shocked as he looks through binoculars on a blue background.

A doctor appears shocked as he looks through binoculars on a blue background.The CSL Limited (ASX: CSL) share price is defying the market selloff and pushing higher on Thursday.

In afternoon trade, the biotherapeutics giant’s shares are up almost 1% to $286.37.

This compares favourably to a 1.4% decline by the ASX 200 index.

Why is the CSL share price outperforming?

Investors have been buying CSL’s shares despite there being no news out of the company.

However, when market volatility is high and the global economic outlook becomes uncertain, companies with defensive earnings are often in favour with investors.

CSL ticks a lot of boxes here. Because it develops life-saving therapies, they are in demand with end-users whatever is happening in the economy.

In addition, plasma is a key ingredient in the company’s therapies. This means that it relies heavily on plasma donations at its collection centres.

When the global economy is booming, there is less need for people to donate plasma. This can lead to CSL having to increase its financial reward for donations. Whereas when there’s an economic downturn, there are more people willing to donate and collection costs tend to reduce accordingly.

The team at Citi is likely to approve of anyone buying CSL shares today. It currently has a buy rating and $350.00 price target on the company’s shares. This implies potential upside of 22% from current levels.

The post Why is the CSL share price smashing the ASX 200 on Thursday? appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of March 1 2023

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/c3qQyP9

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s